61-70 of 81 results
Competition news
In Touch looks at what's been happening in Competition this month and what it means for your business ...
Ambush marketing: traders beware!
Everyone knows the famous adage that 'the enemy of my enemy is my friend'. But can the friend of my friend be my enemy? In the context of ambush marketing, the answer can be yes. ...
Reasonable belief or a mere suspicion? Full Court lowers the bar on preliminary discovery applications
The Full Federal Court has handed down a significant decision on preliminary discovery in a result that will be welcomed by IP owners, as the court has clarified the requirements for a successful preliminary discovery application while emphasising the need for such applications to be met with brevit ...
Room for Improvement? Big Data challenges in Health
'Big data' is revolutionising approaches in all major industries, including the health sector, but Australia's current privacy framework lacks flexibility, and there is insufficient guidance to support compliance. Associate Nick Li looks at the challenges in improving patient care and research outco ...
Allens advises Clearskincare on $127.4m acquisition
Allens has advised the founders of Clearskincare on the sale of the brand's clinic and products businesses to Australian Pharmaceutical Industries (API) for $127.4 million. Under the deal, API will ...
Allens advises PEP on acquisition of LifeHealthcare
Allens has advised private equity fund manager Pacific Equity Partners (PEP) in relation to the acquisition of ASX-listed LifeHealthcare Group Limited (LifeHealthcare) by Pacific Health Supplies ...
Allens advises EBOS Group on acquisition of HPS
Allens has advised EBOS Group Limited on the proposed purchase of HPS, Australia's largest provider of outsourced pharmacy services. The acquisition of HPS - from Blue Sky Private Equity and a numb ...
Isolated genetic material confirmed as patentable
In a unanimous decision the Full Federal Court has confirmed that genetic materials in their isolated form remain patentable in Australia The decision related to an appeal from an earlier Federal Court decision in which it was found isolated nucleic acids to be a manner of manufacture as required by ...
Allens advises Healthscope on sale of Australian pathology business
Allens has acted for one of Australia's leading private healthcare operators, Healthscope Limited, on the sale of its Australian pathology operations to Crescent Capital Partners for $105 million. ...
Allens lends a hand to Global Health
Allens has advised the Global Health Investment Fund ( GHIF ), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately ...